Log in

NASDAQ:PASG - Passage Bio Stock Price, Forecast & News

-1.10 (-8.07 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
Now: $12.53
50-Day Range N/A
52-Week Range
Now: $12.53
Volume76,556 shs
Average Volume596,216 shs
Market Capitalization$551.32 million
P/E RatioN/A
Dividend YieldN/A
Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has a research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
Read More

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:PASG



Sales & Book Value

Annual SalesN/A



Market Cap$551.32 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PASG News and Ratings via Email

Sign-up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter.

Passage Bio (NASDAQ:PASG) Frequently Asked Questions

How has Passage Bio's stock been impacted by COVID-19 (Coronavirus)?

Passage Bio's stock was trading at $18.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PASG stock has decreased by 33.6% and is now trading at $12.53. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Passage Bio?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Passage Bio.

What price target have analysts set for PASG?

4 brokerages have issued 12 month target prices for Passage Bio's shares. Their forecasts range from $25.00 to $30.00. On average, they expect Passage Bio's share price to reach $27.33 in the next twelve months. This suggests a possible upside of 118.1% from the stock's current price. View analysts' price targets for Passage Bio.

Has Passage Bio been receiving favorable news coverage?

Press coverage about PASG stock has been trending very negative on Saturday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Passage Bio earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news aboutPassage Bio.

Who are some of Passage Bio's key competitors?

What other stocks do shareholders of Passage Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), QUALCOMM (QCOM), Alector (ALEC), Beam Therapeutics (BEAM), Editas Medicine (EDIT), MeiraGTx (MGTX), Moderna (MRNA), Bill.com (RVMD) and Schrodinger (SDGR).

Who are Passage Bio's key executives?

Passage Bio's management team includes the following people:
  • Dr. Stephen P. Squinto, Co-Founder, Acting Head of R&D and Director (Age 64)
  • Mr. Alexandros Fotopoulos, Chief Technical Officer
  • Dr. Gary Romano M.D., Ph.D., Chief Medical Officer (Age 59)
  • Dr. Bruce A. Goldsmith, CEO, Pres & Director (Age 54)
  • Dr. James M. Wilson, Co-Founder & Chief Scientific Advisor (Age 65)

When did Passage Bio IPO?

(PASG) raised $126 million in an initial public offering on Friday, February 28th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Chardan was co-manager.

What is Passage Bio's stock symbol?

Passage Bio trades on the NASDAQ under the ticker symbol "PASG."

When does Passage Bio's quiet period expire?

Passage Bio's quiet period expires on Wednesday, April 8th. Passage Bio had issued 12,000,000 shares in its public offering on February 28th. The total size of the offering was $216,000,000 based on an initial share price of $18.00. During Passage Bio's quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Passage Bio?

Shares of PASG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Passage Bio's stock price today?

One share of PASG stock can currently be purchased for approximately $12.53.

How big of a company is Passage Bio?

Passage Bio has a market capitalization of $551.32 million. Passage Bio employs 20 workers across the globe. View additional information about Passage Bio.

What is Passage Bio's official website?

The official website for Passage Bio is http://www.passagebio.com/.

How can I contact Passage Bio?

Passage Bio's mailing address is TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103. The company can be reached via phone at 267-866-0311 or via email at [email protected]

MarketBeat Community Rating for Passage Bio (NASDAQ PASG)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  9 (Vote Outperform)
Underperform Votes:  3 (Vote Underperform)
Total Votes:  12
MarketBeat's community ratings are surveys of what our community members think about Passage Bio and other stocks. Vote "Outperform" if you believe PASG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PASG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: What is a put option?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel